Literature DB >> 18159069

Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1.

Robert Ramer1, Burkhard Hinz.   

Abstract

BACKGROUND: Cannabinoids, in addition to having palliative benefits in cancer therapy, have been associated with anticarcinogenic effects. Although the antiproliferative activities of cannabinoids have been intensively investigated, little is known about their effects on tumor invasion.
METHODS: Matrigel-coated and uncoated Boyden chambers were used to quantify invasiveness and migration, respectively, of human cervical cancer (HeLa) cells that had been treated with cannabinoids (the stable anandamide analog R(+)-methanandamide [MA] and the phytocannabinoid delta9-tetrahydrocannabinol [THC]) in the presence or absence of antagonists of the CB1 or CB2 cannabinoid receptors or of transient receptor potential vanilloid 1 (TRPV1) or inhibitors of p38 or p42/44 mitogen-activated protein kinase (MAPK) pathways. Reverse transcriptase-polymerase chain reaction (RT-PCR) and immunoblotting were used to assess the influence of cannabinoids on the expression of matrix metalloproteinases (MMPs) and endogenous tissue inhibitors of MMPs (TIMPs). The role of TIMP-1 in the anti-invasive action of cannabinoids was analyzed by transfecting HeLa, human cervical carcinoma (C33A), or human lung carcinoma cells (A549) cells with siRNA targeting TIMP-1. All statistical tests were two-sided.
RESULTS: Without modifying migration, MA and THC caused a time- and concentration-dependent suppression of HeLa cell invasion through Matrigel that was accompanied by increased expression of TIMP-1. At the lowest concentrations tested, MA (0.1 microM) and THC (0.01 microM) led to a decrease in invasion (normalized to that observed with vehicle-treated cells) of 61.5% (95% CI = 38.7% to 84.3%, P < .001) and 68.1% (95% CI = 31.5% to 104.8%, P = .0039), respectively. The stimulation of TIMP-1 expression and suppression of cell invasion were reversed by pretreatment of cells with antagonists to CB1 or CB2 receptors, with inhibitors of MAPKs, or, in the case of MA, with an antagonist to TRPV1. Knockdown of cannabinoid-induced TIMP-1 expression by siRNA led to a reversal of the cannabinoid-elicited decrease in tumor cell invasiveness in HeLa, A549, and C33A cells.
CONCLUSION: Increased expression of TIMP-1 mediates an anti-invasive effect of cannabinoids. Cannabinoids may therefore offer a therapeutic option in the treatment of highly invasive cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18159069     DOI: 10.1093/jnci/djm268

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  69 in total

1.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

2.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

Review 3.  Spinal cord injury induced neuropathic pain: Molecular targets and therapeutic approaches.

Authors:  Dominic Schomberg; Gurwattan Miranpuri; Tyler Duellman; Andrew Crowell; Raghu Vemuganti; Daniel Resnick
Journal:  Metab Brain Dis       Date:  2015-01-15       Impact factor: 3.584

Review 4.  Cannabinoids, endocannabinoids, and cancer.

Authors:  Daniel J Hermanson; Lawrence J Marnett
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 5.  Cannabidiol as potential anticancer drug.

Authors:  Paola Massi; Marta Solinas; Valentina Cinquina; Daniela Parolaro
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

6.  Potentiation of the antitumor activity of adriamycin against osteosarcoma by cannabinoid WIN-55,212-2.

Authors:  Feng Niu; Song Zhao; Chang-Yan Xu; Hui Sha; Gui-Bin Bi; Lin Chen; Long Ye; Ping Gong; Tian-Hong Nie
Journal:  Oncol Lett       Date:  2015-07-23       Impact factor: 2.967

Review 7.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

8.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

9.  Expression and function of fatty acid amide hydrolase in prostate cancer.

Authors:  Michael P Endsley; Rebecca Thill; Iffat Choudhry; Carol L Williams; Andre Kajdacsy-Balla; William B Campbell; Kasem Nithipatikom
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

10.  A population-based case-control study of marijuana use and head and neck squamous cell carcinoma.

Authors:  Caihua Liang; Michael D McClean; Carmen Marsit; Brock Christensen; Edward Peters; Heather H Nelson; Karl T Kelsey
Journal:  Cancer Prev Res (Phila)       Date:  2009-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.